Ask AI
ProCE Banner Activity

How to Implement Earlier Hepatitis B Treatment

Podcast Episodes

Listen as Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, review strategies for more expansive HBV treatment while considering adverse events, cost-effectiveness, and patient perspectives. 

Released: March 26, 2024

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with Hepatitis B Foundation

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

Hepatitis B Foundation

ProCE Banner

Disclosure

Primary Author

Jacki Chen, PhD

Patient Advocate

Jacki Chen, PhD: consultant/advisor/speaker: GlaxoSmithKline.

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology/Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York

Tatyana Kushner, MD, MSCE: consultant/advisor/speaker: AbbVie, Aligos, GlaxoSmithKline; researcher: Gilead.

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD: consultant/advisor: Aligos, Drug Farm, Eiger, Galapagos, Gilead, HEPQuant, Inventiva, Mallinckrodt, Mirum, Surrozen; researcher: Altimmune, Eiger, Gilead, Novo Nordisk; individual publicly traded stocks/stock options: Durect.

Mark Sulkowski, MD, FAASLD

Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark Sulkowski, MD, FAASLD: consultant/advisor/speaker: AbbVie, Aligos, GSK, Precision Biosciences, Vir, Virion; data and safety monitoring board: Gilead; researcher: Aligos, GSK, Vir.